C. Le Péchoux

Active 1991–2025

118
Papers
20,004
Citations
71
h-index
116
i10-index

Citations

Citations per year for C. Le Péchoux1971: 2 citations1994: 2 citations1995: 2 citations1996: 1 citations1997: 1 citations1998: 2 citations1999: 2 citations2000: 5 citations2001: 10 citations2002: 8 citations2003: 22 citations2004: 25 citations2005: 19 citations2006: 11 citations2007: 28 citations2008: 28 citations2009: 29 citations2010: 64 citations2011: 61 citations2012: 74 citations2013: 104 citations2014: 104 citations2015: 128 citations2016: 157 citations2017: 165 citations2018: 106 citations2019: 528 citations2020: 792 citations2021: 673 citations2022: 513 citations2023: 302 citations2024: 554 citations2025: 232 citations2026: 7 citations1972–1993: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,263 citing papers, 18.3% of this breakdownChina: 698 citing papers, 10.1% of this breakdownFrance: 535 citing papers, 7.7% of this breakdownItaly: 472 citing papers, 6.8% of this breakdownUnited Kingdom: 460 citing papers, 6.7% of this breakdownGermany: 390 citing papers, 5.6% of this breakdownNetherlands: 388 citing papers, 5.6% of this breakdownCanada: 287 citing papers, 4.2% of this breakdownSpain: 247 citing papers, 3.6% of this breakdownSwitzerland: 202 citing papers, 2.9% of this breakdownBelgium: 190 citing papers, 2.7% of this breakdownJapan: 189 citing papers, 2.7% of this breakdown
0%18.3%Other 23.1%

Fields

  • Medicine83.1%
  • Biochemistry, Genetics and Molecular Biology7.2%
  • Engineering2.8%
  • Physics and Astronomy2.7%
  • Materials Science1.2%
  • Immunology and Microbiology1%
  • Other2%

Topics

  • Lung Cancer Diagnosis and Treatment9.5%
  • Lung Cancer Treatments and Mutations8.5%
  • Lung Cancer Research Studies8.1%
  • Sarcoma Diagnosis and Treatment6.2%
  • Cancer Immunotherapy and Biomarkers4.9%
  • Brain Metastases and Treatment2.9%
  • Other59.9%

Coauthors

All papers

Open in search
  1. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lore Lapeire, Sorin Dema, Gabriel Kacsó, Lyn Austen, Laurence Moureau-Zabotto, Vincent Servois, Eva Wardelmann, Philippe Terrier, Alexander J. Lazar, Judith V.M.G. Bovée, C. Le Péchoux, Z. Papaï - The Lancet Oncology 2019 cited by 503

  2. Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 cited by 1,879

  3. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 cited by 570

  4. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 478

  5. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 cited by 482

  6. Surgery in reference centers improves survival of sarcoma patients: a nationwide study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Emmanuelle Bompas, Christine Chevreau, Florence Duffaud, María Rios, Christophe Perrin, Nelly Firmin, François Bertucci, C. Le Péchoux, François Le Loarer, Olivier Collard, Marie Karanian, Mehdi Brahmi, Armelle Dufresne, Aurélien Dupré, Françoise Ducimetière, Antoine Giraud, David Pérol, Maud Toulmonde, Isabelle Ray‐Coquard, Antoîne Italiano, Axel Le Cesne, Nicolas Penel, Sylvie Bonvalot - Annals of Oncology 2019 cited by 332

  7. Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission

    Authors: , , , , , , , , , , - New England Journal of Medicine 1999 cited by 1,706

  8. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anita Hiltbrunner, Mariana Pardo-Contreras, A. Gasca-Ruchti, Nino Giacomelli, Roswitha Kammler, Nesa Marti, Rita Pfister, Anne‐Christine Piguet, Susanne Roux, Sandra Troesch, M. Schneider, Robin Schweri, Isabel Zigomo, Zoi Tsourti, Panagiota Zygoura, S. Tsouprou, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Franck Morin, Elodie Amour, G. Mariaule, N. Archirel, María Dolores Arnaiz Fernández, E. Pereira, M. Fernandez, K. Lopez, Ainhoa Hernández, Sarah Chinchen, H. Jurkovic, Alan S. Livingstone, Jerry W. Mitchell, Macie B. Walker, Paul Mitchell, S. Ng, Christopher Steer, Karen Briscoe, Amina Saqib, Ehtesham Abdi, Baerin Houghton, Kenneth J. O’Byrne, B.R. Chittajallu, Brett Hughes, A. Black, Kristiaan Nackaerts, Henrica M.J. Werner, R. Gervais, Gérard Zalcman, F. Vaylet, P. Merle, I. Monnet, Denis Moro‐Sibilot, Olivier Molinier, Nicolas Girard, P.-J. Souquet, Fabrice Barlési, D. Debieuvre, Hélène Senellart, M. Poudenx, A. Dixmier, Damien Pouessel, Jacques Cadranel, H. Léna, Élisabeth Quoix, S. Friard, Clarisse Audigier-Valette, Julien Mazières, Éric Pichon, Martin Faehling and 20 more - Annals of Oncology 2021 cited by 114

  9. Outcome of Patients with Non–Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2019 cited by 242

  10. A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 cited by 59

  11. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rafael Rosell, Giorgio V. Scagliotti, Lesley Seymour, Frances A. Shepherd, Richard Sylvester, Hirohito Tada, Fumihiro Tanaka, Valter Torri, David Waller, Ying Liang, for the Non-Small Cell Lung Cancer Collaborative Group - Cochrane Database of Systematic Reviews 2015 cited by 366

  12. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

    Authors: , , , , , , , , , , , , , , - The Lancet 2010 cited by 630

  13. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Egbert F. Smit, Peter Meldgaard, Alex A. Adjei, M. Nicolson, Lucio Crinò, Paul Van Schil, Suresh Senan, Corinne Faivre‐Finn, Gaetano Rocco, Paolo Veronesi, Jean-Yves Douillard, Eric Lim, Christophe Dooms, W. Weder, Dirk De Ruysscher, C. Le Péchoux, Paul De Leyn, Virginie Westeel - Annals of Oncology 2014 cited by 495

  14. First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas

    Authors: , , , , , , , , , , , , , , , - Clinical Cancer Research 2016 cited by 234

  15. Radiotherapy for Management of Extremity Soft Tissue Sarcomas: Why, When, and Where?

    Authors: , , , , , , , , - International Journal of Radiation Oncology*Biology*Physics 2012 cited by 260

  16. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , M. Nicolson, Lucio Crinò, Paul Van Schil, Suresh Senan, Corinne Faivre‐Finn, Gaetano Rocco, Giulia Veronesi, Jean-Yves Douillard, Eric Lim, Christophe Dooms, Walter Weder, Dirk De Ruysscher, C. Le Péchoux, Paul De Leyn, Virginie Westeel - Annals of Oncology 2015 cited by 398

  17. Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mikaela Dimitriu, Patricia Said, Alexander J. Lazar, Judith V.M.G. Bovée, C. Le Péchoux, Z. Papaï - International Journal of Radiation Oncology*Biology*Physics 2022 cited by 44

  18. Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2009 cited by 396

  19. Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma Carried Out at High-Volume Centers is Safe and is Associated With Improved Local Control

    Authors: , , , , , , , , , , , - Annals of Surgical Oncology 2010 cited by 330

  20. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2013 cited by 245

  21. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer

    Authors: , , , , , , , , - Radiotherapy and Oncology 2017 cited by 214

  22. Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France

    Authors: , , , , , , , , , , , , , , , , , , , - European Journal of Cancer 2016 cited by 163

  23. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors

    Authors: , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2019 cited by 133

  24. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 cited by 76